Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.

Deans ZC, Tull J, Beighton G, Abbs S, Robinson DO, Butler R.

Genet Test Mol Biomarkers. 2011 Nov;15(11):777-83. doi: 10.1089/gtmb.2010.0239. Epub 2011 Aug 18.

PMID:
21851273
2.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

3.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.

JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.

PMID:
20978259
4.

Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.

Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY.

Clin Cancer Res. 2009 Jul 1;15(13):4508-13. doi: 10.1158/1078-0432.CCR-08-3179. Epub 2009 Jun 23.

5.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

6.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

7.

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.

Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN.

Arch Pathol Lab Med. 2009 Oct;133(10):1600-6. doi: 10.1043/1543-2165-133.10.1600. Review.

PMID:
19792050
8.

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.

Value Health. 2013 Mar-Apr;16(2):288-96. doi: 10.1016/j.jval.2012.11.001. Epub 2013 Jan 23.

9.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
10.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.

Br J Cancer. 2010 Mar 30;102(7):1137-44. doi: 10.1038/sj.bjc.6605612. Epub 2010 Mar 16.

11.

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme.

Dequeker E, Ligtenberg MJ, Vander Borght S, van Krieken JH.

Virchows Arch. 2011 Aug;459(2):155-60. doi: 10.1007/s00428-011-1094-x. Epub 2011 Jun 24.

PMID:
21701884
12.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
13.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
14.

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

Blank PR, Moch H, Szucs TD, Schwenkglenks M.

Clin Cancer Res. 2011 Oct 1;17(19):6338-46. doi: 10.1158/1078-0432.CCR-10-2267. Epub 2011 Aug 1.

15.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A.

Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.

16.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
17.

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].

Nozawa K, Watanabe T.

Gan To Kagaku Ryoho. 2010 May;37(5):791-4. Japanese.

PMID:
20495308
18.

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, Gorgoulis V, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E.

Oncologist. 2011;16(4):467-78. doi: 10.1634/theoncologist.2010-0429. Epub 2011 Mar 26.

19.

KRAS status predicts response to cetuximab for metastatic colorectal cancer.

McBride D.

ONS Connect. 2008 Aug;23(8):25. No abstract available.

PMID:
18767573
20.

KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.

Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G.

J Clin Pathol. 2015 Apr;68(4):265-9. doi: 10.1136/jclinpath-2014-202761. Epub 2015 Jan 21.

PMID:
25609577

Supplemental Content

Support Center